NL-OMON48798
Not Yet Recruiting
N/A
PROSPEC study; PROstate cancer follow-up care in Secondary and Primary hEalth Care - PROSPEC study
ederlands Kanker Instituut0 sites390 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ederlands Kanker Instituut
- Enrollment
- 390
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Men diagnosed with invasive prostate cancer;
- •\- Stage cT1a \- cT3; pNx \- pN1; R0\-1 having completed primary treatment
- •(prostatectomy or radiotherapy);
- •\- Radiotherapy with or without androgen deprivation therapy (ADT) for localized
- •prostate cancer
- •\- No evidence of recurrence (PSA\<0\.1 ng/ml after prostatectomy or PSA\<
- •nadir\+2\.0 ng/mL after radiotherapy).
Exclusion Criteria
- •\- Primary treatment (prostatectomy, radiotherapy) completed longer than 6
- •months previously;
- •\- Patients under active surveillance;
- •\- Under investigation for possible recurrence (patients become eligible if
- •recurrence is ruled out);
- •\- Does not have a community\-based GP to provide care;
- •\- Unable to comply with study protocol including completion of questionnaires;
- •\- Actively followed by a cancer specialist for another primary cancer;
- •\- (Previously) enrolled in a study requiring ongoing follow\-up by a cancer
- •specialist;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390
Unknown
N/A
Follow-up study for localized prostate cancer treated by hormonal therapy or radical prostatectomy.Prostate cancerJPRN-UMIN000000570J-CaP study group2,000
Completed
N/A
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyProstate CancerNCT05759273Ipsen167
Active, Not Recruiting
Phase 1
Study on patients with recurrence of prostate cancer with PET/MRRadically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)MedDRA version: 21.1Level: LLTClassification code 10026389Term: Malignant neoplasm of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001036-21-ITOSPEDALE SAN RAFFAELE60
Completed
Phase 2
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerProstate CancerNCT01558427University Hospital, Ghent62